Home

Aadi Bioscience, Inc. - Common Stock (AADI)

2.1000
-0.1100 (-4.98%)

Aadi Biosciences Inc is a biotechnology company focused on developing and commercializing innovative therapies for patients with cancer

The company specializes in creating targeted treatments that aim to enhance the efficacy and safety of cancer care, particularly for individuals with difficult-to-treat tumors. By leveraging advanced drug development techniques and a deep understanding of cancer biology, Aadi Biosciences strives to address unmet medical needs and improve outcomes for patients battling various forms of cancer. Through its research and clinical trials, the company is dedicated to delivering comprehensive solutions that ultimately aim to transform the landscape of oncology treatment.

SummaryNewsPress ReleasesChartHistoricalFAQ
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Investors were all spooked today with Dow plummeting more than 500 points. The primary cause can be attributed to inflation fears, disappointing earnings, and booming bond yields. Tech stocks drove the Dow down with the NASDAQ skidding 2.6 percent and the S&P 500 index falling 1.8 percent. The Dow closed down 1.5 percent. With the market selling off, it’s may very well be time to dive into biotech stocks currently trading at bargain prices. Some of the best value biotech stocks coupled with growth and momentum that needs to make the top of the Biotech Stock list include Brickell Biotech Inc (NASDAQBBI), Intercept Pharmaceuticals Inc. NASDAQ:ICPTNASDAQICPT)(NASDAQ:AKBANASDAQAKBA, uniQure NV (NASDAQ:QURENASDAQ), BioNTech SE (NASDAQ:BNTXBNTX), Seres Therapeutics Inc. (NASDAQMCRB), Marinus Pharmaceuticals Inc. NASDAQ:MRNSNASDAQMRNS)(NASDAQ:AADINASDAQAADI, Cassava Sciences Inc. (NASDAQ:SAVANASDAQ). During the past year, biotech stocks, as represented by the iShares Biotechnology ETF (IBB), have posted a total return of -12.8%, significantly below the Russell 1000's total return of 21.0% as of Jan. 13, 2022. However, 2022 could very well be a turning point for the biotech charts to run up.
Via AB Newswire · January 19, 2022